The Future of the Treatment of TNBC

News
Video

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).

Clinical Pearls

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).

  • BRCA-like or basal-like breast cancer that is triple-negative is particularly aggressive. Platinums may be more effective in this space.
  • Many pharmaceutical companies are not looking at PARP inhibitors in large studies because of the results of 1 negative trial.
  • Many TNBCs have downregulation of BRCA proteins where inhibiting PARP may be particularly effective.
  • Some studies are also looking at antibodies and antibody-directed therapies to inhibit the NOTCH pathway.
Recent Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content